Enemeez® Pharmacoeconomic Evaluation

Overview

A study conducted by the VA investigated the mean duration and quality of bowel care when comparing bisacodyl suppository and the docusate sodium mini-enema. In a randomized and non-randomized controlled trial, findings revealed a notable decrease in bowel care time when using a docusate sodium mini-enema compared to a bisacodyl suppository.

Treatment Outcome Cost Comparison Summary

Clinical Outcomes Impacting Facility Costs

Bisacodyl users are twice as likely to have an episode of incontinence following a bowel care session when compared to docusate sodium mini-enema users.

 

A pharmacoeconomic evaluation showed that when using Enemeez®, some patients reduced their bowel care time by 1 hour or more daily, thus reducing the time needed for a personal care attendant.

  • In addition, the reduced time spent on a commode may reduce the risk of pelvic ulcer development. Incontinent patients are 22 times more likely to develop a pressure ulcer. The cost to treat can be upwards of $70,000.
  • Prolonged bowel care time or fatigue after bowel care often interferes with a patient’s participation in therapy

Cost Comparison Summary

Implementaion of Enemeez Chart   Implementation of Bisacodyl Suppository

Bowel Care Time Summary

Study supported that patients using the docusate sodium mini-enemahad a bowel movement almost twice as fastas patients using a bisacodyl suppository. Time from flatus to total transfer of patient.

  Time comparison chart

Clinical Pharmacoeconomics

What does an ineffective bowel care protocol cost your facility?

  1. The total annual labor and supply cost in 2002 per long term care resident with constipation was $2,253.8*
  2. 46% of long-term care residents experience fecal incontinence on a regular basis.
  3. The mean time spent each day dealing with incontinence was 52.5 minutes per patient or $27.19 per day, per patient.

The total annual cost of incontinence per patient was $16,976.

Enemeez Medicaid Coverage Map

download pdf version